Year 2017 / Volume 109 / Number 12
Original
Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain

809-817

DOI: 10.17235/reed.2017.5063/2017

Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado,

Abstract
Objective: To assess the long-term healthcare costs and health outcomes in association with the access to new direct-acting antivirals (DAAs), during the first year of the National Strategic Plan for Chronic Hepatitis C (SPCHC) in patients with chronic hepatitis C (CHC) in Spain. Methods: A decision tree and a lifetime Markov model were developed to simulate the natural history, morbidity, and mortality of a cohort of 51,900 patients with CHC before (pre-DAA strategy) and after (post-DAA strategy) access to DAAs, following SPCHC approval. The percentage of patients treated, transition probabilities, disease management costs, health state utility values, sustained virologic response rates and treatment costs were obtained from the literature and published data from Spain. The results were expressed in terms of costs (€, 2016), quality-adjusted life years (QALYs) and prevention of clinical events, with an annual discount rate of 3%. Results: The post-DAA strategy would prevent 8,667 cases of decompensated cirrhosis, 5,471 cases of hepatocellular carcinoma, 1,137 liver transplants and 9,608 liver-related deaths. The cohort of 51,900 patients would require investments of 1,606 and 1,230 million euros with the post-DAA and pre-DAA strategies, respectively. This would produce 819,674 and 665,703 QALYs. Conclusions: The use of new DAA-based treatments in CHC patients during the first year after the implementation of the SPCHC significantly reduced long-term morbidity and mortality and increased quality of life; demonstrating that this plan is an efficient use of public health resources.
Share Button
New comment
Comments
No comments for this article
References
1. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014; 21 Suppl 1: 34-59.
2. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1: 74-81.
3. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1patients. J Hepatol. 2014; 60: 530-7.
4. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053): 1775-1812.
5. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016; 388: 1081-8.
6. García-Fulgueiras A, García-Pina R, Morant C, García-Ortuzar V, Genova R, Alvarez E. Hepatitis C and hepatitis B-related mortality in Spain. Eur J Gastroenterol 2009; 21: 895-901.
7. García-Fulgueiras A, García-Pina R, Morant C, de Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problema. J Viral Hepat 2011; 18: e453-60.
8. Crespo J, Cabezas J, Sacristán B, Olcoz JL, Pérez R, De la Vega J, et al. Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice. Liver Int. 2015; 35: 401-8.
9. Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012; 143: 974-85.
10. González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016; 22: 1421-32.
11. Asociación Española para el Estudio del Hígado. Guías AEEH/SEIMC de manejo de la Hepatitis C. 2016; cited 2016 26th Ago]. Available form: http://aeeh.es/wp-content/uploads/2016/06/Gu%C3%ADas_AEEH_SEIMC_VersionFinal.pdf
12. European Association for the Study Liver (EASL). Recommendations on treatment of hepatitis C 2015. Clinical practice guidelines. [cited 2016 03th Oct]. Available from: http://www.easl.eu/. Published 2015.
13. Spanish Ministry of Health, Social Policy and Equality. Plan Estratégico para el abordaje de la Hepatitis C [Internet]. [cited 2016 23th Feb]. Available from: http://www.msssi.gob.es
14. Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Rev Gastroenterol Hepatol. 2016; 10:1227-34.
15. Calvaruso V, Craxi A. Why do I treat my patients with mild hepatitis C? Liver Int 2016; 36 (Suppl. S1): 7-12.
16. Hézode C. Why I do not treat patients for mild disease. Liver Int 2016; 36 (Suppl. S1): 13-20.
17. Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, et al. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. Hepatology. 2015; 62: 31-9.
18. Adinolfi LE, Guerrera B. All-oral interferón-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol. 2015; 7: 2363-8.
19. Buti M, Domínguez-Hernández R, Oyagüez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12704.
20. Spanish Ministry of Health, Social Policy and Equality. Institute for Health Information. Press releases, 2016 [Internet] [cited 2016 23th Feb]. Available from: http://www.msssi.gob.es/gabinete/notasPrensa.do?id=3909.
21. Turnes J, Domínguez-Hernández R, Casado MA. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C: before and after access to direct-acting antiviral in Spain. Gastroenterol Hepatol. Gastroenterol Hepatol. 2017;40:433-446.
22. Buti M, San Miguel R, Brosa M, Cabasés JM, Medina M, Casado MA, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol. 2005; 42: 639-45.
23. Puente Á, Cabezas J, López Arias MJ, Fortea JI, Arias MT, Estébanez Á, Casafont F, Fábrega E, Crespo J. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. Rev Esp Enferm Dig. 2017;109:17-25.
24. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 2016; 176: 65-73.
25. Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, et al. Boceprevir for previously untreated patients with chronic hepatitis C genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis. 2013; 13: 190.
26. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008; 135: 8219.
27. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010; 16: 748-59.
28. San Miguel R, Gimeno-Ballester G, Blázquez A, Mar J. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2015; 64: 1277–88.
29. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015; 41: 544-63.
30. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, et a. Priorization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol 2016; 65: 17-25.
31. Spanish General Council of Official Colleges of Pharmacists - Bot PLUS 2.0 [cited 2016 23th May]. Available from: https://botplusweb.portalfarma.com/.
32. Ministry of Finance and Public Administration. Update on the stability program 2016-2019 [internet]. [cited 2016 23th Feb] Available from: http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan_estrategico_hepatitis_C.pdf
33. Buti M, Gros B, Oyagüez I, Andrade RJ, Serra MA, Turnes J, et al. [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients]. Farm Hosp. 2014; 38(5): 418-29.
34. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart, GL, editors. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
35. López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010; 11: 513-20.
36. Catalá F., García-Altés A. Algunas consideraciones metodológicas en la evaluación económica de intervenciones preventivas: un debate abierto. PharmacoEconomics - Spanish Research Articles.2008;5: 61-65.
37. Van Nuys K, Brookmeyer R, Chou JW, Dreyfus D, Dieterich D, Goldman DP. Broad hepatitis C treatment scenarios return substantial health gains, but capacity is a concern. Health Aff (Millwood) 2015; 34: 1666-74.
38. Sacristán JA, Oliva J, del Llano J, Prieto L, Pinto JL. What is an efficient health technology in Spain Gac Sanit. 2002; 16: 334-43.
39. Vallejo-Torres L, García-Lorenzo B, Castilla I, Valcárcel C, García-Pérez L, Linertová R, et al. Valor Monetario de un Año de Vida Ajustado por Calidad: Estimación empírica del coste de oportunidad en el Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud; 2015. Informes de Evaluación de Tecnologías Sanitarias.
40. Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther. 2016;5: 491-508.
41. Arganda C. El gasto farmacéutico crece por debajo del PIB y la industria no devolverá. DiarioFarma, Madrid: 2017, enero 23. [online]. Disponible en: https://www.diariofarma.com/2017/01/23/gasto-farmaceutico-crece-debajo-del-pib-la-industria-no-devolvera.
42. Porter ME. What is value in health care? N Engl J Med. 2010; 363: 2477-81.
43. McMahon LF Jr, Chopra V. Health care cost and value: the way forward. JAMA 2012; 307: 671-2.
44. Vernaz N, Girardin F, Goossens N, Brügger U, Riguzzi M, et al. (2016) Drug Pricing Evolution in Hepatitis C. PLoS ONE 11: e0157098.
45. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, et al. European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016; 65: 524-31.
46. Jena AB, Stevens W, Gonzalez YS, Marx SE, Juday T, Lakdawalla DN, et al. The wider public health value of HCV treatment accrued by liver transplant recipients. Am J Manag Care. 2016; 22: SP212-9.
47. Sociedad Española de Trasplante Hepático (SETH). Registro Español de Trasplante Hepático. Memoria de resultados 2015. Memoria trasplante hepático 2015. [citado 10 Nov 2016]. Disponible en: http://www.sethepatico.org
48. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332–42.
49. Tang L, Marcell L, Kottilil S. Systemic manifestations of hepatitis C infection. Infect Agent Cancer. 2016 May 23; 11: 29.
50. Younossi Z, Brown A, Buti M, Fagiuoli S, Mauss S, Rosenberg W, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat 2016; 23: 217-26.
Related articles

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Citation tools
Turnes J, Domínguez-Hernández R, Casado M. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. 5063/2017


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1205 visits.
This article has been downloaded 316 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 18/05/2017

Accepted: 04/09/2017

Online First: 20/11/2017

Published: 04/12/2017

Article revision time: 105 days

Article Online First time: 186 days

Article editing time: 200 days


Share
This article has been rated by 2 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology